Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary

Oncology Reports

Volumn 16, Issue 6, 2006, Pages 1301-1306

  Takano, Masashi ^a,k   Kikuchi, Yoshihiro ^a   Yaegashi, Nobuo ^b   Suzuki, Mitsuaki ^c   Tsuda, Hiroshi ^d   Sagae, Satoru ^e   Udagawa, Yasuhiro ^f   Kuzuya, Kazuo ^g   Kigawa, Junzo ^h   Takeuchi, Satoshi ⁱ   Tsuda, Hitoshi ^a   Moriya, Takuya ^b   Sugiyama, Toru ^j  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f FUJITA HEALTH UNIVERSITY   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h TOTTORI UNIVERSITY   (Japan)

ⁱ NHO Kobe National Hospital   (Japan)

^j IWATE MEDICAL UNIVERSITY   (Japan)

^k HAMMERSMITH HOSPITAL   (United Kingdom)

more..

Author keywords

Adjuvant chemotherapy; Clear cell carcinoma; Irinotecan hydrochloride; Multicentre; Ovarian cancer; Paclitaxel; Retrospective

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; IRINOTECAN; PACLITAXEL; PLATINUM DERIVATIVE;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; GYNECOLOGIC SURGERY; HUMAN; MIDDLE AGED; MORTALITY; OVARY TUMOR; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36348936967     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.6.1301     Document Type: Article

References (29)

1. Schiller W: Mesonephroma ovarii. Am J Cancer 35: 1-21, 1939.
2. Serov SF, Scully RE and Sobin LH: International histologic classification of tumors. In: Histologic Typing of Ovarian Tumors. World Health Organization, Geneva, No. 9, 1973.
3. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C and Wiltshaw E: Clear cell epithelial ovarian carcinoma cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 49: 250-254, 1993. (Pubitemid 23170001)
4. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ and Park RC: Long-term follow-up prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experiences. J Clin Oncol 9: 1138-1150, 1991.
5. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE and Fuller AF Jr: Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60: 412-417, 1996. (Pubitemid 26077628)
6. Recio FO, Piver MS, Hempling RE and Driscoll DL: Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus non-platinum-based chemotherapy. Cancer 78: 2157-2163, 1996. (Pubitemid 26367609)
7. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88: 2584-2589, 2000.
8. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T and Dimopoulos MA: Advanced stage clear-cell epithelial ovarian cancer: the Hellenic cooperative oncology group experience. Gynecol Oncol (In press).
9. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY and Hsieh CY: Puretype clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94: 197-203, 2004.
10. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y and Yaegashi N: Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16: 52-56, 2006.
11. Ho CM, Chien TY, Shih BY and Huang SH: Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 88: 394-399, 2003.
12. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tshuda H, Moriya T and Sugiyama T: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374, 2006. (Pubitemid 43772268)
13. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S and Miura Y: Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50: 604-610, 1992.
14. Minagawa Y, Kigawa J, Ishihara H, Itamochi H and Terakawa N: Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 85: 966-971, 1994. (Pubitemid 24294757)
15. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M and Saijo N: Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Cancer Res 56: 789-793, 1996.
16. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N; Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Eng J Med 346: 85-91, 2002. (Pubitemid 34438898)
17. Adachi S, Ogasawara T, Yamasaki N, Shibahara H, Kanazawa R, Tsuji Y, Takemura T and Koyama K: A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 29: 434-437, 1999.
18. Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J, Tode T and Nagata I: Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep 7: 327-331, 2000.
19. Sugiyama T, Yakushiji M, Nishida T, Ushijima K, Okura N, Kigawa J and Terakawa N: Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128: 211-218, 1998. (Pubitemid 28318738)
20. Jinno H, Saeki M, Saito Y, Tanaka-Kagawa T, Hanioka N, Sai K, Kaniwa N, Ando M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Ozawa S and Sawada J: Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 306: 688-693, 2003. (Pubitemid 36886169)
21. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T and Saijo N: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75: 501-515, 2004. (Pubitemid 38746601)
22. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 334: 1-6, 1996. (Pubitemid 26012496)
23. Bookman MA, Greer BE and Ozols RF: Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. Int J Gynecol Cancer 13: 735-740, 2003. (Pubitemid 38235216)
24. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J and Birrer MJ: Gene expression profiles of serous, endometrioid and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 15: 6422-6430, 2005. (Pubitemid 41338978)
25. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr and Lu KH: Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11: 6116-6126, 2005. (Pubitemid 41262937)
26. Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y and Terakawa N: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 93: 723-728, 2002. (Pubitemid 34846281)
27. Nishino K, Aoki Y, Amikura T, Obata H, Sekine M, Yahata T, Fujita K and Tanaka K: Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell carcinoma. Gynecol Oncol 97: 893-897, 2005. (Pubitemid 40824662)
28. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y and Hirohashi S: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163: 2503-2512, 2003. (Pubitemid 37466491)
29. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ and Mok SC: Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinoma by cDNA microarray analysis. Clin Cancer Res 11: 6880-6888, 2005. (Pubitemid 41428744)